Literature DB >> 11521128

A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men.

B Lamarche1, A C St-Pierre, I L Ruel, B Cantin, G R Dagenais, J P Després.   

Abstract

BACKGROUND: The current interpretation of the increased risk of ischemic heart disease (IHD) associated with reduced low density lipoprotein (LDL) particle size is based entirely on data derived from relatively small case-control studies, with a lack of evidence from large, prospective, population-based cohort data.
OBJECTIVES: To investigate the association between LDL particle size and incident IHD on the basis of data from the entire population-based, prospective cohort of men from the Quebec Cardiovascular Study. PATIENTS AND METHODS: Analyses were conducted in a cohort of 2057 men who were all initially free of IHD, and who were followed up over a five-year period, during which 108 first IHD events (myocardial infarction, angina or coronary death) were recorded. LDL particle size was measured by nondenaturing gradient gel electrophoresis.
RESULTS: Cox proportional hazards analysis indicated that the relationship between LDL particle size and the risk of future IHD events was not linear. Men with an LDL particle size less than 256.0 A had a significant 2.2-fold increase in the five-year rate of IHD (P<0.001) compared with men having an LDL particle size greater than 256.0 A. Multivariate and subgroup analyses indicated that small, dense LDL particles predicted the rate of IHD independent of LDL cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, apolipoprotein B and the total cholesterol to HDL cholesterol ratio. Finally, the magnitude of the increase in IHD risk attributed to lipid risk factors was modulated to a significant extent by variations in LDL particle size.
CONCLUSIONS: The present study provides the first large scale, population-based, prospective evidence supporting the hypothesis that small, dense LDL particles may be associated with an increased risk of IHD. The results also suggest that information on LDL diameter may improve the ability to predict IHD risk accurately over traditional lipid variables.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521128

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  19 in total

1.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

2.  The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR).

Authors:  Jasmin Divers; Michèle M Sale; Lingyi Lu; Wei-Min Chen; Kerry H Lok; Ida J Spruill; Jyotika K Fernandes; Carl D Langefeld; W Timothy Garvey
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

3.  LDL particle heterogeneity, and its association with other established cardiovascular risk factors in a young Indian industrial population.

Authors:  Ramakrishnan Lakshmy; Prabhakaran Dorairaj; Mohamad Tarik; Ruby Gupta; Kolli Srinath Reddy
Journal:  Heart Asia       Date:  2012-10-16

Review 4.  Revisiting dietary cholesterol recommendations: does the evidence support a limit of 300 mg/d?

Authors:  Maria Luz Fernandez; Mariana Calle
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

5.  Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.

Authors:  San-Chiang Wu; Jeng-Chuan Shiang; Shoa-Lin Lin; Te-Lang Wu; Wei-Chun Huang; Kuan-Rau Chiou; Chun-Peng Liu
Journal:  Heart Vessels       Date:  2005-09       Impact factor: 2.037

6.  Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross-over, randomized, double-blind, controlled inpatient physiology study.

Authors:  Dario Tuccinardi; Olivia M Farr; Jagriti Upadhyay; Sabrina M Oussaada; Maria I Klapa; Marco Candela; Simone Rampelli; Sylvain Lehoux; Iolanda Lázaro; Aleix Sala-Vila; Patrizia Brigidi; Richard D Cummings; Christos S Mantzoros
Journal:  Diabetes Obes Metab       Date:  2019-07-02       Impact factor: 6.577

7.  Serum small dense low-density lipoprotein concentrations are elevated in patients with significant coronary artery stenosis and are related to features of the metabolic syndrome.

Authors:  Shima Yazdandoust; Seyyed Mohammad Reza Parizadeh; Mohsen Moohebati; Parichehreh Yaghmaei; Amir Ali Rahsepar; Shima Tavallaie; Mohammad Soukhtanloo; Roshanak Khojasteh; Roghayeh Paydar; Afsoon Fazlinezhad; Homa Falsoleiman; Mashalla Dehghani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Lipids       Date:  2012-08-18       Impact factor: 1.880

Review 8.  Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Authors:  Toshikazu Yamanouchi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 9.  Dietary fats and health: dietary recommendations in the context of scientific evidence.

Authors:  Glen D Lawrence
Journal:  Adv Nutr       Date:  2013-05-01       Impact factor: 8.701

Review 10.  Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.

Authors:  Stanley Ip; Alice H Lichtenstein; Mei Chung; Joseph Lau; Ethan M Balk
Journal:  Ann Intern Med       Date:  2009-04-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.